, Tracking Stock Market Picks
Enter Symbol:
Heron Therapeutics Inc. (HRTX) [hlAlert]

up 1.95 %

Heron Therapeutics Inc. (HRTX) rated Outperform with price target $57 by Leerink Partners

Posted on: Wednesday,  Sep 23, 2015  10:25 AM ET by Leerink Partners

Leerink Partners rated Outperform Heron Therapeutics Inc. (NASDAQ: HRTX) on 09/23/2015. Previously Leerink Partners rated Outperform Heron Therapeutics Inc. (NASDAQ: HRTX) on
06/19/2015., when the stock price was $32.76. Since then, Heron Therapeutics Inc. has gained 1.95% as of 01/19/2016's recent price of $33.40.
If you would have followed the previous Leerink Partners's recommendation on HRTX, you would have gained 1.95% of your investment in 214 days.

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company?s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.

Leerink Partners
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/23/2015 10:25 AM Buy
40.83 57.00
as of 8/27/2015
1 Week up  11.17 %
1 Month up  10.65 %
3 Months up  7.17 %
1 YTD up  7.17 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/19/2015 10:25 AM Buy
32.76 38.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy